Abstract
Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.
Keywords: inflammation, il-1, anti-tnf agents, t-cell depletion, cytotoxic-lymphocyte-associated antigen 4, anti-osteoclast therapies
Current Medicinal Chemistry
Title: Antibody Treatments of Inflammatory Arthritis
Volume: 12 Issue: 25
Author(s): Matthew A. Brown
Affiliation:
Keywords: inflammation, il-1, anti-tnf agents, t-cell depletion, cytotoxic-lymphocyte-associated antigen 4, anti-osteoclast therapies
Abstract: Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.
Export Options
About this article
Cite this article as:
Brown A. Matthew, Antibody Treatments of Inflammatory Arthritis, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462842
DOI https://dx.doi.org/10.2174/092986705774462842 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Immune Disturbances in Chronic Pain: Cause, Consequence or Both?
Current Immunology Reviews (Discontinued) Computational and Experimental Progress on the Structure and Chemical Reactivity of Procyanidins: Their Potential as Metalloproteinases Inhibitors
Current Organic Chemistry Effects of High-Fat Diets from Different Sources on Serum and Thymus Lipid Profile: Study in an Experimental Model
Endocrine, Metabolic & Immune Disorders - Drug Targets The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Autoantibodies for Cardiac Channels and Sudden Cardiac Death and its Relationship to Autoimmune Disorders
Current Cardiology Reviews Value of Magnetic Resonance T1 Mapping in Evaluating the Early Response to Treatment for Rheumatoid Arthritis
Current Medical Imaging Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Xylopic Acid Suppresses Adjuvant-induced Arthritis in Sprague Dawley Rats via Reduction in Serum Levels of IL-6 and TNF-alpha
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Mini-Reviews in Medicinal Chemistry Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Sleep and the Immune System
Current Immunology Reviews (Discontinued) The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
Current Medicinal Chemistry - Anti-Cancer Agents Synergistic Effect of Piperine and its Derivatives: A Comprehensive Review
Current Drug Research Reviews Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry